Intestinal microbiocenosis in patients with recurrent Clostridium difficile infection, ulcerative colitis and irritable bowel syndrome after transplantation of fecal microflora

Identified significant changes in the intestinal microbiome in patients with inflammatory bowel disease (IBD), serve as the reason for therapeutic interventions in order to correct it. Faecal microbiota transplantation (TFM) is an effective treatment for recurrent or refractory Clostridium difficile infections, including in patients with inflammatory bowel diseases receiving immunosuppressive and anticytokine therapy.The results of studying the effectiveness of TFM using a filtered aqueous suspension of donors feces in the correction of intestinal microbiocenosis in patients with recurrent Clostridial infection (RCT), ulcerative colitis (UC) and irritable bowel syndrome (IBS) are presented. 2 weeks after the introduction of the supernatant, a suspension of fecal microorganism microorganisms in patients evaluated the dynamics of the total content of microorganisms and individual representatives of the intestinal microflora. It was found that the supernatant of an aqueous suspension of donor feces containing microbial exometabolites and other biologically active compounds in the short term has the most pronounced effect on the restoration of normal intestinal microflora only in patients with clostridial infection.

Download Full-text

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms

Arquivos de Gastroenterologia ◽

10.1590/s0004-28032015000100011 ◽

2015 ◽

Vol 52 (1) ◽

pp. 50-54 ◽

Cited By ~ 8

Author(s):

Lorete Maria da Silva KOTZE ◽

Renato Mitsunori NISIHARA ◽

Sandra Beatriz MARION ◽

Murilo Franco CAVASSANI ◽

Paulo Gustavo KOTZE

Keyword(s):

Ulcerative Colitis ◽

Irritable Bowel Syndrome ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Inflammatory Bowel Diseases ◽

Fecal Calprotectin ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Irritable Bowel ◽

Active Disease

Background Determination of fecal calprotectin can provide an important guidance for the physician, also in primary care, in the differential diagnosis of gastrointestinal disorders, meanly between inflammatory bowel diseases and irritable bowel syndrome. Objectives The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of fecal calprotectin as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of inflammatory bowel diseases. Methods The study included consecutive patients who had gastrointestinal complaints in which the measurement levels of fecal calprotectin were recommended. Fecal calprotectin was measured using a Bühlmann (Basel, Switzerland) ELISA kit Results A total of 279 patients were included in the study, with median age of 39 years (range, 18 to 78 years). After clinical and laboratorial evaluation and considering the final diagnosis, patients were allocated into the following groups: a) Irritable Bowel Syndrome: 154 patients (102 female and 52 male subjects). b) Inflammatory Bowel Diseases group: 112 patients; 73 with Crohn’s disease; 38 female and 35 male patients; 52.1% (38/73) presented active disease, and 47.9% (35/73) had disease in remission and 39 patients with ulcerative colitis;19 female and 20 male patients; 48.7% (19/39) classified with active disease and 49.3% (20/39) with disease in remission. A significant difference (P<0.001) was observed between the median value of fecal calprotectin in Irritable Bowel Syndrome group that was 50.5 µg/g (IQR=16 - 294 µg/g); 405 µg/g (IQR=29 - 1980 µg/g) in Crohn’s disease patients and 457 µg/g (IQR=25 - 1430 µg/g) in ulcerative colitis patients. No difference was observed between the values found in the patients with Crohn’s disease and ulcerative colitis. Levels of fecal calprotectin were significantly lower in patients with inflammatory bowel diseases in remission when compared with active disease (P<0.001). Conclusions The present study showed that the determination of fecal calprotectin assists to differentiate between active and inactive inflammatory bowel diseases and between inflammatory bowel diseases and irritable bowel syndrome.

Download Full-text

Fecal microbiota transplantation. Prospects in pediatric practice

Voprosy detskoj dietologii ◽

10.20953/1727-5784-2021-3-37-45 ◽

2021 ◽

Vol 19 (3) ◽

pp. 37-45

Author(s):

E.S. Pimenova ◽

◽

E.M. Mukhametova ◽

E.Ya. Musaeva ◽

S.I. Erdes ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Clostridium Difficile ◽

Short Bowel Syndrome ◽

Fecal Microbiota Transplantation ◽

Fecal Microbiota ◽

Pediatric Practice ◽

Short Bowel ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Irritable Bowel

The aim of this review is to summarize data on the experience of using fecal microbiota transplantation (FMT) as a method of treating intestinal diseases, in particular in pediatric practice. FMT is the process of transferring fecal material from a healthy donor to the recipient’s gastrointestinal tract in order to alter gut microbial composition. To date, the most amount of research has been conducted in the field of treatment for Clostridium difficile infection. The mortality rate among children with this pathology is 1–5%. Randomized clinical trials show a higher efficacy of FMT compared to the use of antibiotics (efficacy rates of 90% and 26%, respectively) in the treatment for C. difficile infection. The effectiveness of FMT as a treatment for other diseases has been discussed. Cases of the successful use of FMT as a treatment for short bowel syndrome in children have been described, and studies on the effectiveness of this technique in patients with irritable bowel syndrome and inflammatory bowel diseases have been conducted. Most studies have been carried out on small samples of patients, and the results vary. The potential of using FMT as a treatment of children with severe bowel diseases is high, which makes it necessary to conduct further research in pediatric practice. Key words: inflammatory bowel disease, Clostridium difficile infection, short bowel syndrome, irritable bowel syndrome, fecal microbiota transplantation

Download Full-text

IBS-Symptoms in IBD Patients—Manifestation of Concomitant or Different Entities

Journal of Clinical Medicine ◽

10.3390/jcm10010031 ◽

2020 ◽

Vol 10 (1) ◽

pp. 31

Author(s):

Patrycja Szałwińska ◽

Jakub Włodarczyk ◽

Antonino Spinelli ◽

Jakub Fichna ◽

Marcin Włodarczyk

Keyword(s):

Ulcerative Colitis ◽

Irritable Bowel Syndrome ◽

Crohn’S Disease ◽

Abdominal Pain ◽

Inflammatory Bowel Diseases ◽

Clinical Remission ◽

Gut Motility ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Irritable Bowel

Irritable bowel syndrome (IBS) is a functional heterogenous disease with a multifactorial pathogenesis. It is characterized by abdominal pain, discomfort, and alteration in gut motility. The occurrence of similar symptoms was observed in patients in clinical remission of inflammatory bowel diseases (IBD) that is Crohn’s disease (CD) and ulcerative colitis (UC), which pathogenesis is also not fully understood. Hence, arose the question if these symptoms are “true IBS” imposed on IBD, or is it a subclinical form of IBD or even pre-IBD? In this article, based on a narrative overview of the literature, we try to find an answer to this query by discussing the pathogenesis and overlaps between these conditions.

Download Full-text

CLOSTRIDIUM DIFFICILE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME AND ULCERATIVE COLITIS

The Lancet ◽

10.1016/s0140-6736(82)92305-4 ◽

1982 ◽

Vol 319 (8281) ◽

pp. 1124 ◽

Cited By ~ 7

Author(s):

Michael Tvede ◽

Lars Willumsen

Keyword(s):

Ulcerative Colitis ◽

Irritable Bowel Syndrome ◽

Clostridium Difficile ◽

Irritable Bowel

Download Full-text

Application Potential of Polymeric Nanoconstructs for Colon-Specific Drug Delivery

Multifunctional Nanocarriers for Contemporary Healthcare Applications - Advances in Medical Technologies and Clinical Practice ◽

10.4018/978-1-5225-4781-5.ch002 ◽

2018 ◽

pp. 22-49 ◽

Cited By ~ 3

Author(s):

Sanjay Kumar Jain ◽

Ankita Tiwari ◽

Ankit Jain ◽

Amit Verma ◽

Shivani Saraf ◽

...

Keyword(s):

Colorectal Cancer ◽

Ulcerative Colitis ◽

Drug Delivery ◽

Irritable Bowel Syndrome ◽

Specific Drug ◽

Bowel Diseases ◽

Application Potential ◽

Inflammatory Bowel ◽

Colon Specific Drug Delivery ◽

Irritable Bowel

Numerous applications of colon-specific drug delivery have been found in a wide array of diseases like irritable bowel syndrome (IBS), inflammatory bowel diseases (ulcerative colitis and Crohn's disease), colorectal cancer, and diverticulitis. Drug delivery to the colon has different anatomic and pathophysiological barriers. In recent advancements, these barriers were overcome by using biodegradable polymeric nanoconstructs, which are exhibiting minimal systemic adverse effects. Various polymeric nanoconstructs (PNCs) such as nanoparticles, micelles, and dendrimers have been exploited for effective targeting to pathological sites of colon. PNCs on oral administration not only protect the bioactive from physicochemical degradation but also prevent premature leakage in the upper parts of gastrointestinal tract. The chapter summarizes various PNCs-based approaches for colon-specific drug delivery.

Download Full-text